Evidence map›Paper›PMID 34609195›Full record

Observational studyRadiology2022

CT Lung Abnormalities after COVID-19 at 3 Months and 1 Year after Hospital Discharge.

Bavithra Vijayakumar, James Tonkin, Anand Devaraj, Keir E J Philip, Christopher M Orton, Sujal R Desai, Pallav L Shah

Registry-linked trialAbstract readObservational Study
PubMed Full text at PMC Publisher
In one paragraph

Observational study in Radiology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT04459351 (PHenotyping patiENts Admitted to Hospital With cOvid-19 Infection and idenTifYing Prognostic markErs), which is not on this map. Cited by 81 papers, 6 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
81citing papers in PubMed, 6 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT04459351 unknown statusnot on this map

PHenotyping patiENts Admitted to Hospital With cOvid-19 Infection and idenTifYing Prognostic markErs

TypeobservationalSponsorChelsea and Westminster NHS Foundation TrustRan2020 to 2023Enrolled500ConditionsCoronavirus, Corona Virus Infection, COVID-19, 2019nCoV
3 · Its place in the literature

Who cites it

81 citing papers in PubMed, 6 syntheses or guidelines pooled it.

  1. Pooled it
  2. Post-COVID-19 dyspnoea and pulmonary imaging: a systematic review and meta-analysis.European respiratory review : an official journal of the European Respiratory Society · 2023
    Pooled it
  3. Pooled it
  4. Prevalence, risk factors and treatments for post-COVID-19 breathlessness: a systematic review and meta-analysis.European respiratory review : an official journal of the European Respiratory Society · 2022
    Pooled it
  5. Pooled it
  6. Pooled it
  7. Trial
  8. Article
  9. Article
  10. Article
  11. Article
  12. Article
  13. Review
  14. Article
  15. Article
  16. Article
  17. Article
  18. Article
  19. Article
  20. Article

21 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Bavithra VijayakumarFrom the Department of Respiratory Medicine, Chelsea and Westminster NHS Foundation Trust, 369 Fulham Rd, London SW10 9NH, England (B.V., J.T., C.M.O., P.L.S.); Departments of Respiratory Medicine (B.V., J.T., K.E.J.P., C.M.O., P.L.S.) and Radiology (A.D., S.R.D.), Royal Brompton and Harefield Hospitals, London, England; National Heart and Lung Institute, Imperial College London, London, England (B.V., J.T., A.D., K.E.J.P., C.M.O., S.R.D., P.L.S.); and The Margaret Turner-Warwick Centre for Fibrosing Lung Disease, London, England (S.R.D.).ORCID 0000-0001-7794-3435
James TonkinFrom the Department of Respiratory Medicine, Chelsea and Westminster NHS Foundation Trust, 369 Fulham Rd, London SW10 9NH, England (B.V., J.T., C.M.O., P.L.S.); Departments of Respiratory Medicine (B.V., J.T., K.E.J.P., C.M.O., P.L.S.) and Radiology (A.D., S.R.D.), Royal Brompton and Harefield Hospitals, London, England; National Heart and Lung Institute, Imperial College London, London, England (B.V., J.T., A.D., K.E.J.P., C.M.O., S.R.D., P.L.S.); and The Margaret Turner-Warwick Centre for Fibrosing Lung Disease, London, England (S.R.D.).ORCID 0000-0001-7827-1407
Anand DevarajFrom the Department of Respiratory Medicine, Chelsea and Westminster NHS Foundation Trust, 369 Fulham Rd, London SW10 9NH, England (B.V., J.T., C.M.O., P.L.S.); Departments of Respiratory Medicine (B.V., J.T., K.E.J.P., C.M.O., P.L.S.) and Radiology (A.D., S.R.D.), Royal Brompton and Harefield Hospitals, London, England; National Heart and Lung Institute, Imperial College London, London, England (B.V., J.T., A.D., K.E.J.P., C.M.O., S.R.D., P.L.S.); and The Margaret Turner-Warwick Centre for Fibrosing Lung Disease, London, England (S.R.D.).
Keir E J PhilipFrom the Department of Respiratory Medicine, Chelsea and Westminster NHS Foundation Trust, 369 Fulham Rd, London SW10 9NH, England (B.V., J.T., C.M.O., P.L.S.); Departments of Respiratory Medicine (B.V., J.T., K.E.J.P., C.M.O., P.L.S.) and Radiology (A.D., S.R.D.), Royal Brompton and Harefield Hospitals, London, England; National Heart and Lung Institute, Imperial College London, London, England (B.V., J.T., A.D., K.E.J.P., C.M.O., S.R.D., P.L.S.); and The Margaret Turner-Warwick Centre for Fibrosing Lung Disease, London, England (S.R.D.).ORCID 0000-0001-9614-3580
Christopher M OrtonFrom the Department of Respiratory Medicine, Chelsea and Westminster NHS Foundation Trust, 369 Fulham Rd, London SW10 9NH, England (B.V., J.T., C.M.O., P.L.S.); Departments of Respiratory Medicine (B.V., J.T., K.E.J.P., C.M.O., P.L.S.) and Radiology (A.D., S.R.D.), Royal Brompton and Harefield Hospitals, London, England; National Heart and Lung Institute, Imperial College London, London, England (B.V., J.T., A.D., K.E.J.P., C.M.O., S.R.D., P.L.S.); and The Margaret Turner-Warwick Centre for Fibrosing Lung Disease, London, England (S.R.D.).ORCID 0000-0002-9167-5462
Sujal R DesaiFrom the Department of Respiratory Medicine, Chelsea and Westminster NHS Foundation Trust, 369 Fulham Rd, London SW10 9NH, England (B.V., J.T., C.M.O., P.L.S.); Departments of Respiratory Medicine (B.V., J.T., K.E.J.P., C.M.O., P.L.S.) and Radiology (A.D., S.R.D.), Royal Brompton and Harefield Hospitals, London, England; National Heart and Lung Institute, Imperial College London, London, England (B.V., J.T., A.D., K.E.J.P., C.M.O., S.R.D., P.L.S.); and The Margaret Turner-Warwick Centre for Fibrosing Lung Disease, London, England (S.R.D.).ORCID 0000-0002-5237-3613
Pallav L ShahFrom the Department of Respiratory Medicine, Chelsea and Westminster NHS Foundation Trust, 369 Fulham Rd, London SW10 9NH, England (B.V., J.T., C.M.O., P.L.S.); Departments of Respiratory Medicine (B.V., J.T., K.E.J.P., C.M.O., P.L.S.) and Radiology (A.D., S.R.D.), Royal Brompton and Harefield Hospitals, London, England; National Heart and Lung Institute, Imperial College London, London, England (B.V., J.T., A.D., K.E.J.P., C.M.O., S.R.D., P.L.S.); and The Margaret Turner-Warwick Centre for Fibrosing Lung Disease, London, England (S.R.D.).ORCID 0000-0002-9052-4638

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background Data on the long-term pulmonary sequelae in COVID-19 are lacking. Purpose To assess symptoms, functional impairment, and residual pulmonary abnormalities on serial chest CT scans in COVID-19 survivors discharged from hospital at up to 1-year follow-up. Materials and Methods Adult patients with COVID-19 discharged between March 2020 and June 2020 were prospectively evaluated at 3 months and 1 year through systematic assessment of symptoms, functional impairment, and thoracic CT scans as part of the PHENOTYPE study, an observational cohort study in COVID-19 survivors. Lung function testing was limited to participants with CT abnormalities and/or persistent breathlessness. Bonferroni correction was used. Results Eighty participants (mean age, 59 years ± 13 [SD]; 53 men) were assessed. At outpatient review, persistent breathlessness was reported in 37 of the 80 participants (46%) and cough was reported in 17 (21%). CT scans in 73 participants after discharge (median, 105 days; IQR, 95-141 days) revealed persistent abnormalities in 41 participants (56%), with ground-glass opacification (35 of 73 participants [48%]) and bands (27 of 73 participants [37%]) predominating. Unequivocal signs indicative of established fibrosis (ie, volume loss and/or traction bronchiectasis) were present in nine of 73 participants (12%). Higher admission serum C-reactive protein (in milligrams per liter), fibrinogen (in grams per deciliter), urea (millimoles per liter), and creatinine (micromoles per liter) levels; longer hospital stay (in days); older age (in years); and requirement for invasive ventilation were associated with CT abnormalities at 3-month follow-up. Thirty-two of 41 participants (78%) with abnormal findings at 3-month follow-up CT underwent repeat imaging at a median of 364 days (range, 360-366 days), with 26 (81%) showing further radiologic improvement (median, 18%; IQR, 10%-40%). Conclusion CT abnormalities were common at 3 months after COVID-19 but with signs of fibrosis in a minority. More severe acute disease was linked with CT abnormalities at 3 months. However, radiologic improvement was seen in the majority at 1-year follow-up. ClinicalTrials.gov identifier: NCT04459351. © RSNA, 2022

Indexed as

COVID-19Patient DischargeDyspneaFibrosisHospitalsHumansLungTomography, X-Ray Computed

Identifiers

PMID34609195
PMCPMC8515207

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.